GW Link

Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Neuroimaging and CSF Biomarker Development Program

Grants to USA, Canada, and International Nonprofits,
For-Profits, and IHEs to Advance Alzheimer's Therapy Research

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Alzheimer's Drug Discovery Foundation (ADDF)

LOI Date:

10/11/19

Deadline Date:

11/08/19 5:00 PM ET Receipt

Description:

Request a Grant Writer

Grants to USA, Canada, and International nonprofits, universities, academic medical centers, and biotechnology companies for biomarkers research that will further the development of Alzheimer’s therapies. LOIs must be submitted before applying. New applicants are advised to allow 1-2 business days for registration in the online application portal.

This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use that include but are not limited to:

1. Clearly demonstrate target engagement for novel therapeutics: The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.
2. Detect signs of disease earlier and monitor progression. ADDF is seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. ADDF also seeks prognostic markers that can predict rates of cognitive decline.
3. More accurately diagnose and distinguish between dementia subtypes: Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

Biomarker Targets - Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include, but are not limited to:

- Neurodegeneration
- Vascular injury or blood-brain barrier integrity
- Mitochondria & metabolic function
- Protein misfolding/proteostasis
- Oxidative stress
- White matter changes
- Other novel targets and pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process are encouraged.

All proposals should address the following:

- Potential for Commercial Translation
- Context of Use
- How the Proposed Biomarker Compares to Currently Available Biomarkers

For details on the above areas and on Expectations and Evaluation, see the URL for Full Text link below.

GrantWatch ID#:

GrantWatch ID#: 181960

Estimated Size of Grant:

Average Award: $150,000 - $600,000 based on stage and scope of research; Larger amounts will be considered for PET ligand development for regulatory or clinical work.

Term of Contract:

Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered.

Additional Eligibility Criteria:

Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:

-Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.

-Biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.

ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).

Pre-Application Information:

For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

It is highly recommended that you access the ADDF Funding Portal to begin the application process well in advance of any deadlines. Please note, new applicants should allow 1-2 business days for registration.

Upcoming Deadlines:

Letters of Intent and Full Proposals must be received by 5:00 PM ET on the deadline date.

-Letter of Intent: January 18, 2019
-Invited Full Proposal: February 8, 2019

-Letter of Intent: April 12, 2019
-Invited Full Proposal: May 10, 2019

-Letter of Intent: July 12, 2019
-Invited Full Proposal: August 9, 2019

-Letter of Intent: October 11, 2019
-Invited Full Proposal: November 8, 2019

Application Checklist:
https://www.alzdiscovery.org/research-and-grants/funding-opportunities/application-instructions

Funding Policies:
https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Apply Online:
https://addf.fluxx.io/

For program-related inquiries, please contact:

Meriel Owen, PhD, Scientific Program Officer
mowen@alzdiscovery.org

For application submission inquiries, please contact:

Grants and Mission-Related Investments Team
212.901.8019
grants@alzdiscovery.org

URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

USA Territories: American Samoa (USA)   Guam (USA)   Puerto Rico (USA)   Virgin Islands (USA)   Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon

Israel

International country outside of the USA, Israel and Canada.